COSMOS Pharmaceutical Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from COSMOS Pharmaceutical Corporation's yearly results (2023–2026), compared with Healthcare companies in Japan. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: ¥11 per ¥100 of sales comes from others' credit, against ¥12 from others' credit three years earlier. Less money tied up than 96% of Healthcare companies in Japan.
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 92% of Healthcare companies in Japan.
- Tangible Assets Ratio: Of every ¥100 the company owns, ¥100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 91% of Healthcare companies in Japan.
Where ¥100 of sales goes
Latest year (May 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
¥190Over the last 3 years, every ¥100 of reported profit came with ¥190 of operating cash.
Higher than 82% of Healthcare companies in Japan.
Self-Funding Ratio
0.9×Over the last 3 years its own operating cash paid for 93% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 63% of Healthcare companies in Japan.
Cash Locked Ratio
−¥11Money owed to suppliers is larger than money owed by customers plus stock: ¥11 per ¥100 of sales comes from others' credit, against ¥12 from others' credit three years earlier.
Less money tied up than 96% of Healthcare companies in Japan.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 92% of Healthcare companies in Japan.
Growth Efficiency Ratio
¥3Sales grew 33% in 3 years; of every extra ¥100 of sales, ¥3 became extra profit.
Lower than 56% of Healthcare companies in Japan.
Asset Productivity Ratio
+33% / +42%In 3 years sales changed by +33% while total assets changed by +42%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
6.7×Debt due within a year is covered 6.7 times by its yearly operating cash.
Higher than 85% of Healthcare companies in Japan.
Cash Cushion Ratio
−4%Debt, after subtracting cash, equals 4% of its market value (net debt).
Lower than 62% of Healthcare companies in Japan.
Tangible Assets Ratio
100%Of every ¥100 the company owns, ¥100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 91% of Healthcare companies in Japan.
Tangible Net Worth Ratio
100%Of every ¥100 of net worth, ¥100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 86% of Healthcare companies in Japan.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
COSMOS Pharmaceutical Corporation owes ¥0.51 for every ¥1 it owns. Net profit rose 3% in the year to May 2026, and grew 10% a year on average over 3 years.
Compared with Healthcare companies in Japan · latest annual results May 2026.
P/E ratio
15.1Investors pay ¥15.1 for every ¥1 of COSMOS Pharmaceutical Corporation's yearly profit, lower than 56% of Healthcare companies in Japan.
P/B ratio
1.67The share price is 1.67 times COSMOS Pharmaceutical Corporation's book value per share, higher than 54% of Healthcare companies in Japan.
Market cap
¥481.0 BThe total market value of all of COSMOS Pharmaceutical Corporation's shares at today's price (share price × number of shares), larger than 90% of Healthcare companies in Japan. PosiCap size class: Meso Cap.
Net worth (book value)
¥288.4 BWhat COSMOS Pharmaceutical Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Aug 2026).
Book value per share
¥3,639Net worth divided by the number of shares. The share price of ¥6,069 is 1.7 times this, which is the P/B above.
Return on equity (ROE)
11.7%COSMOS Pharmaceutical Corporation earned 11.7% on its shareholders' money over the last year, higher than 72% of Healthcare companies in Japan.
Owes vs Owns
0.51×COSMOS Pharmaceutical Corporation owes ¥0.51 for every ¥1 it owns (moderate), higher than 64% of Healthcare companies in Japan.
Dividend yield
1.39%COSMOS Pharmaceutical Corporation pays 1.39% of its share price as dividends a year, lower than 86% of dividend-paying Healthcare companies in Japan.
Revenue growth
+9%Revenue rose 9% in the year to May 2026, and grew 10% a year on average over 3 years.
Profit growth
+3%Net profit rose 3% in the year to May 2026, and grew 10% a year on average over 3 years.
Profit margin
2.9%COSMOS Pharmaceutical Corporation keeps ¥3 of every ¥100 of revenue as net profit.
Cash quality
1.8×Cash from COSMOS Pharmaceutical Corporation's business was 1.8× its reported profit in the year to May 2026 — its profit turned into cash.
Interest cover
72.9×COSMOS Pharmaceutical Corporation's operating profit covered its interest costs 72.9 times in the year to May 2026.
Cash vs debt
Net debtCOSMOS Pharmaceutical Corporation had ¥17.1 B more debt than cash (net debt) at May 2026.
Questions
What is COSMOS Pharmaceutical Corporation's P/E ratio?
Investors pay ¥15.1 for every ¥1 of COSMOS Pharmaceutical Corporation's yearly profit, lower than 56% of Healthcare companies in Japan.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For COSMOS Pharmaceutical Corporation: ¥481.0 B ÷ ¥288.4 B (31 Aug 2026) = 1.7.
What is COSMOS Pharmaceutical Corporation's return on equity?
COSMOS Pharmaceutical Corporation earned 11.7% on its shareholders' money over the last year, higher than 72% of Healthcare companies in Japan.
How much does COSMOS Pharmaceutical Corporation owe compared with what it owns?
COSMOS Pharmaceutical Corporation owes ¥0.51 for every ¥1 it owns (moderate), higher than 64% of Healthcare companies in Japan.
Does COSMOS Pharmaceutical Corporation pay a dividend?
Yes. COSMOS Pharmaceutical Corporation pays 1.39% of its share price as dividends a year, lower than 86% of dividend-paying Healthcare companies in Japan.
Is COSMOS Pharmaceutical Corporation's revenue growing?
Revenue rose 9% in the year to May 2026, and grew 10% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.